ALZFORUM

From Specialized to Standardized: Social-Emotional Tests for FTD

One person “checks out” from family, seeming reluctant to talk. Another talks incessantly, without saying much. One person seems unaware of the emotions of others; another recognizes emotions but ...
ALZFORUM

First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running

First, the bad news. Claude Wischik of the University of Aberdeen, Scotland, who leads TauRx Pharmaceuticals, described a lack of efficacy for the company’s compound LMTM in patients with behavioral ...
Business Wire

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference Regulatory T cell (Treg) immunomodulatory function significantly ...
Seeking Alpha

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF ...
Seeking Alpha

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved ...
Nasdaq

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines significantly increased in FTD patients COYA 302, Coya’s lead investigational ...